Our goal is to identify molecules that regenerate beta-cell mass and prevent beta-cell dysfunction and death. We also develop broadly-applicable chemical technologies with the intent of applying these technologies to specific avenues in beta cell biology...
David R. Liu is the Richard Merkin Professor and director of the Merkin Institute of Transformative Technologies in Healthcare, vice-chair of the faculty at the Broad Institute of MIT and Harvard, the Thomas Dudley Cabot Professor of the Natural Sciences...
Genome editing may provide a lasting treatment for many genetic disorders by correcting disease mutations or making compensatory changes to the genome. We develop platforms using genome editing tools to investigate cellular mechanisms of neurodegeneration...
Our central goal is to develop novel chemical biology and functional genomic approaches to illuminate molecular mechanisms in epigenetics and gene regulation, while exploring the promise of chromatin regulators as therapeutic targets for cancer.
The Liau...
The laboratory focuses on systematic characterization of genetic variants to understand the regulation of barrier defense, innate and adaptive immunity; chemical biology to control cellular disease phenotypes suggested by human genetics; molecular...
The Ubiquitin Proteasome System (UPS) is involved in virtually any cellular process and frequently implicated in human pathologies. Ubiquitin, through the action of a three-enzyme cascade (E1, E2 and E3), becomes attached to substrate proteins. The...
